Comparative pharmacology of rosuvastatin
- 15 March 2003
- journal article
- review article
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 4 (1) , 9-14
- https://doi.org/10.1016/s1567-5688(03)00004-7
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Statin inhibition of HMG-CoA reductase: a 3-dimensional viewAtherosclerosis Supplements, 2003
- Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjectsBritish Journal of Clinical Pharmacology, 2003
- Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trialAmerican Heart Journal, 2002
- Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemiaAmerican Heart Journal, 2002
- The effect of fluconazole on the pharmacokinetics of rosuvastatinEuropean Journal of Clinical Pharmacology, 2002
- Rosuvastatin reduces atherosclerosis independently of its cholesterol-lowering effect in apoE∗Leiden transgenic miceAtherosclerosis Supplements, 2002
- A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acidBritish Journal of Pharmacology, 2001
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis, 2000